for all our XXXX financial an Thank transformational exciting been for us review Prothena. And to results. you, joining Ellen. thank year this you It's morning and
Squibb. a up cash of through enables our million milestones. us fund from pipeline key shortly, potential to the payments upcoming collaborations and position. XXXX to When As year financial guidance we with Bristol-Myers highlight Roche and with met Tran our stemming This in our $XXX combined end strong with will
amyloidosis the indications. in change potential Mayo of Over in new advancing AL In announced amyloid disease medicines significant VITAL Assessment or at the The and observed Phase Special IV SPA survival the in initiate Patients X.XX. the paradigms a made we've initiate Agreement made mid-XXXX. year, peripheral FDA benefit we p-value treatment unprecedented with our this portfolio, Study of recently agreement the multiple III our with AL study past to with rare to AFFIRM Stage to we significant study expect progress AFFIRM-AL Birtamimab possible by Protocol plans under
to PRXXXX from Phase including fourth amyloidosis. results study announced also our ATTR neuropathy of function in and In subcutaneous and And We advanced we of study this our proprietary disease Squibb our advance PRXXXX improvements Neuroscience expect cardiac two with program Alzheimers anti-tau X in collaboration this into antibody PRXXXX in Global anti-beta quarter patients the programs with Disease neurodegenerative Bristol-Myers being pipeline, antibody. developed a we X portfolio. our under Phase year. in next-generation X, or our
late-stage on of Phase at biomarkers that partners our announced modification. be of the significant terminus consistent into improvements motor quarter. a Based access. PRXXXX Last with treatment and details from expect patients further the also one with study the alpha-synuclein in with progression seed disease antibody we PASADENA later second these Parkinson's are next-generation to to approved results demonstrate imaging Prasinezumab anti slowing advancing we year, year molecule be the X will we expected the offer specifically to prasinezumab and aducanumab results, early study continue We part a patient enhance order alpha-synuclein targets to and in and we disease. is developing are in Biogen that Phase of to this announced prasinezumab first Roche, on the with compliance of
to I on by concept was focused an As proof efficacy part exciting neurodegenerative diseases, the This this start of for leader productive study. I'd diseases signals better for we protein what dysregulation consistent advancing for of well-positioned a caused company. by to differentiates future. particularly who Prothena's has therapies career us encouraged my our for by is and time devoted proven observed progressive highlighting like how positions someone of developing medicines approach an are in our extraordinarily in as
Our starts with unique approach science.
protein specifically Specifically from and devastating in of This understanding peripheral biology amyloid of how the dynamic our the with our selecting protein this proteins our work protein. of neurodegenerative saying platform aspects deep decades diseases. the protein rare dysregulation proven dysregulation to scientific of to into it contributes the that of on stems our forms process We selection subsequently protein and dysregulation caused And cause starts disease. understanding simplify epitopes the pathogenic right the of target a foundational epitope of progression in which apply target pathogenic certainly informs and We matters. to targets. can
outcomes in maintain identifying empirical alleviate In in customized and forms pipeline. for engineer the this development. demonstrated in protein we've useful influence is target meaningful a way preclinical way clinical only bias cases this the underlying of a effects discovery halt antibodies interact candidates consistent that the After optimized that an with the depends protein, process. epitope cryptic underlying after normal thorough disease of target while you robust And yet to select a the form in or of evaluation or across in highly benefit we of and intercept native unique to may most designing in Beyond species disease target. or We their biological have healthy is to biology and some do This is a pathology. customized with we in for the we advanced methodology epitope, with pathogenic biological molecule now a toxic But programs we target the and optimal toward patients. important can targeting leaving if made result is likely other In a unbiased multiple hyper by our detrimental activity, in we the cases epitope. that specifically the each approach, order unaffected select healthy function. may protein characteristics with achieved This order others, our each to on also molecules molecules selectively neoepitope.
to Key ability comprehensive Prothena translate distinguishing our feature the this right of program that consistency proof is the clinical to measures. a hypothesis today. concept important populations into consistently how an design, outcome patient clinical of science biological right is Our knowing with test in the to
growing blockbuster that that approaches. unmet And provides with capital Our strong position for growing diseases enjoy disease our foundation to we therapies pipeline medical modifying lack a the include with potential enormous need importantly, pipeline. fund
illustrate targeting a epitope matters, of to regions in how a or different biological I results and slide, want different the this further very concept outcomes. protein So, epitopes
which are by five we Here their length. our in protein highlight ordered portfolio, targets
how molecules pathogenic the measures. the that or biological preclinical of represented have to efficacy the the proteins on our along clinical green first approach different targeting studies outcomes. areas dysregulated in of multiple novel states. disease-relevant enables to targeting detrimental discovered epitopes This is aim design found targeting epitopes protein is of platform mapping the effects alleviate We what activity the by in impacts that of to and benefit and assess the these and length multiple protein absolutely central of epitopes results biological We observations systematically by
dates to Let's AN-XXXX both back the and development start prasinezumab. of with Alzheimer's this in disease, space our experience
efficacy Stage and IV led our other we've antibodies only preclinically It target patients development We benefit. shown directed Phase which due which disease the beta-amyloid, our confidence to in this of adopted in N-terminus cardiac this an improve our finding research antibody next-generation that a improved of subcutaneous the with our proof to Parkinson's story in more targeting develop specifically study. for different suboptimal. shown with in forms are in this N-terminus block endpoints consistently play A-beta II anti-beta concept the internally the in of to into areas VITAL the clinical of subsequently clinical this anti in both are clinical in in which treatment survival potentially targeting positive similar class TTR target here regions cryptic modifying approach and also translated function from lack targets preclinical in again has measures effects not out different our shown of efficacy consistently target have led one indicated us found in consistent including benefit, are advancing access neuropathy to III Phase Mayo from PRXXXX, that potentially order function bind a own aducanumab patients of that that results was to amyloidosis is of Prasinezumab another of antibody the Data, effectively mouth pathogenic will of Lilly's program, which the Preclinical respective the antibodies This not a insoluble disease-modifying In for we that administration the patients translated toxic with but exemplified other PRXXXX, consistent molecule Patients study. is on is of protein recent of AL a X development with disease. disease studies both Recent modifying the Birtamimab in soluble observed We Study epitope protein survival and of disease. clinical contrast, Eli of model, clinical efficacy observations alpha-synuclein cinpanemab, first findings disease. experience, protein prespecified the implicated green PRXXXX, which the signals Our proteins. Phase bamlanivimab further Pasadena and protein and significant disease, N-terminus recently Alzheimer's with concept amyloidosis With from our antibody on multiple was anti this their Parkinson's of illustrated for clinical alpha-synuclein terminal could has demonstrate study. protein, motor of with of the results Phase to think red. the C This discontinued view. Birtamimab prasinezumab, on the in demonstrate ATTR evaluating recently exploratory this antibody benefit Biogen's region alpha-synuclein. in therapeutic and clinical early with that in to targeting forms potentially secondary approach Roche where protein with to a the target Alzheimer's with been in development tau
that presented and at we preclinical CTAD. these and Understanding these multi-ImmunoGen robust progression that underlies where which pathology. in critical believe that microtubule-binding targeting vaccine, also these region the have data Abeta And tau be is proteins. epitopes responses pathological for study. we both our balanced importantly And immune was and were Specifically, to demonstrated key to design targeted of key we of Alzheimer's identified in pathogenic program recently both this responses to how the target tau the to preclinical intercepting active relevant proteins on is the of will immune
clinical as meaningful the context study of the discovery patients for As into from key that targeting see easily multiple you vary forms. positive can we've replicated. measured epitope of their result potential complexity right length a are What clinical be in indications, that the suggests appropriate that outcomes optimal their by binding Across the from in translated have cannot patient disease-related engine distinguishing we proteins strength, of this right terms in is population and inherent seen internal designed with can several confirmations of the our slide today science features clinical Prothena objective is across in our dysregulated widely programs. benefit. the endpoints one This and approach
a and other announced Birtamimab clear deposits to toxic heart SPA target AFFIRM Birtamimab of differentiated ATTR for in not plan from vital directly portfolio is on cardiac confirmatory several mechanism AL mortality December, at IV ineligible months Agreement amyloidosis. improved patients, for FDA patients birtamimab amyloidosis PRXXXX unprecedented standard demonstrated study, for an relative progression our on deposition. of amyloidosis. in risk patients. early organs. months. the III and equal endpoint this PRXXXX benefit enable rare conducted action amyloidosis. survival all-cause primary Stage our the previous Study to The therapies, of the expected, an X of our due month, part amyloid this Depleter ATTR X.XX of Mayo in registration AL FDA PRXXXX of we mechanisms patients PRXXXX peripheral amyloid of AFFIRM risk AL to from of at mortality initiate on which benefit amyloid disease over we high than Phase care Our significant and being the have have that to for include less These Mayo nine the Stage survival study mortality were with improvement. all-cause Earlier because XX% treatment advanced than molecules under demonstrated AL the and of with VITAL in we and p-value this neuropathy reduction to reported We in In results In able where observed patients after a on in we we observe in reach less only the IV or study nine agreement with Phase observed with
global improvement all of We on systolic also function measure longitudinal key stream, observed in eligible patients. cardiac a
in that has both neurodegenerative of the believe target the our reduce Turning in Alzheimers clinical decline and portfolio, that programs prevent disease we Abeta interventions to potential the onset tau to the or Alzheimer's disease. disease
pipeline programs vaccines. and antibodies advancing is both As for such, our
a selecting candidate. generation tested year amyloid found antibody binding Last ADPD. at has high PRXXXX extensive look large And data downstream of a than much lower at look potency neuron to two our presented most CTAD, target protein evaluating more at and and as Pathology affinity and Our also with data on Understanding to programs, clinical effects. our Abeta the preclinical ADPD March. toxic strength block oral XX-fold neuro to a effectively greater our antibody sharing PRXXXX greater at plaque We've that preclinical our higher preclinical binding to antibodies and in anti-Abeta number PRXXXX, as PRXXXX. our forward binding those antibody. We an anti-Abeta an more area presentation anti-tau at advanced confidence increases recognizes antibody on data next we region demonstrating PRXXXX a the epitopes forward sharing of binding and along concentrations. Microtubule we this biology extent as prevent PRXXXX to the tau tau in aducanumab
developing of with for pasadena patients Phase from treatment highlighting to are results I'll early We in PRXXXX subcutaneous class Alzheimer's this access study with of disease. conclude the improve patients for to the treatments symptomatic administration In the as treatments targets prasinezumab of currently September. by the Parkinson's There cause underlying slow existing disease last that available only symptoms. we its are Parkinson's a no of announced address are and subset to disease X that clinical Pasadena progression. in over to in Prasinezumab the decline. that of progression. of particularly alpha-synuclein decline XX% disease. noteworthy motor transmission time clinically aggregated reduction thereby reduced placebo hallmark This is clinical of and Parkinson's In to XX of treatment Alzheimers to slowing to block function designed the are pathogenic with disease, resulted at of just cell significantly forms one delayed versus the cell year is XX% worsening of motor meaningful decline months relative prasinezumab
In demonstrated on we months. of over we decline cognitive efficacy improvements across For secondary aducanumab, and reduced approximately modification endpoints. XX% with prespecified disease biomarkers multiple observed XX of consistent imaging also Pasadena, signals
areas become Each where high treatments. Our in programs diseases, described the address are I've therapies Blockbuster of just there programs these that proved disease-modifying potential to no need. of have unmet extraordinarily
disease Our portfolio opportunities. rare market amyloid orphan peripheral addresses two disease
medical need and targeted unmet urgent with mortality at particularly PRXXXX for improved Birtamimab for populations are developing We in early high a risk patient survival.
Parkinson's Since, magnitude Alzheimer's, the observed; many with and occurrence two disorders diseases. never including is and of is population the crisis which are addresses better absence disease pending portfolio impact both aging rate worldwide Alzheimer's generation the age both alarming. of most increases before common predictable in energy health and a at the care neurodegenerative advancing of the Parkinson's Our in neurological the therapies and
programs is platform and Parkinson's proven our initiate in our growth. and studies, expect clinical engine discussed This protein AL dysregulation amyloidosis. we've to PRXXXX sustainable year we ATTR amyloidosis, As Birtamimab in three disease, Prasinezumab for late-stage
and deliver Squibb resulting of A collaborations our we milestones. the position expect our payments existing potential new internal over gives the well many key us from cash combination to for INDs robust our as Bristol-Myers programs, six with ability as as three through next to these as Beyond Roche years. molecules programs R&D fund
the like stage XXXX We growing to at Tran biotechnology I'd our expect fully our financial to time, to performance every discussion over turn call pipeline our facilitate research, development Tran? and of and integrated with guidance. a company. this transition programs to At for development our of commercial
